Article
Fully searchable access to the November 1, 2009 issue
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
How food choices may affect non-refractive visual impairment
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
RhyGaze secures Series A financing of $86 million to further novel gene therapy
Ashvattha Therapeutics secures $50M in financing to advance clinical trials